by
Gus Iversen, Editor in Chief | February 23, 2026
Danaher has agreed to acquire Masimo Corp. in an all-cash transaction valued at approximately $9.9 billion, including assumed debt and net of acquired cash.
The Washington-based life sciences and diagnostics company said it will pay $180 per share for the Irvine, California-based patient monitoring manufacturer.
The deal values Masimo at roughly 18 times its estimated 2027 EBITDA, or about 15 times EBITDA when expected synergies are included.
Ad Statistics
Times Displayed: 5006
Times Visited: 14 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
Masimo develops pulse oximetry and other monitoring technologies used primarily in acute care settings. Following the close, the company will operate as a stand-alone business within Danaher’s diagnostics segment, alongside Radiometer, Leica Biosystems, Cepheid and Beckman Coulter Diagnostics.
Rainer M. Blair, president and CEO of Danaher, said: “We are excited to welcome the Masimo team to Danaher. We've followed this innovative company for many years and see it as an exceptional strategic fit for Danaher. Masimo is a leader in pulse oximetry and other patient monitoring solutions, which, combined with its trusted brand and differentiated technology, will greatly strengthen our diagnostics franchise. With the Danaher Business System and our global scale, we see opportunities to expand Masimo's reach and continue improving outcomes for patients, particularly those in acute care settings.”
Julie Sawyer Montgomery, executive vice president for diagnostics at Danaher, said: “Masimo's advanced sensor technology and AI-enabled monitoring bring powerful new capabilities to our diagnostics portfolio. Integrating these strengths into Danaher will create meaningful opportunities to innovate for clinicians and improve decision-making in critical settings.”
Danaher expects Masimo to contribute more than $530 million in EBITDA in 2027. The company projects more than $125 million in annual cost synergies and more than $50 million in annual revenue synergies by the fifth full year after closing. The acquisition is expected to be accretive to adjusted diluted net earnings per share by $0.15 to $0.20 in the first full year and about $0.70 by year five.
The transaction is expected to close in the second half of 2026, subject to regulatory approvals and Masimo shareholder approval. Danaher plans to finance the purchase with cash on hand and debt financing. Citi advised Danaher, with Goldman Sachs providing additional advisory support. Kirkland & Ellis LLP served as legal counsel.
